Diabetes Mellitus, Type 1
Conditions
Keywords
Diabetes Mellitus, Type 1 (new-onset), T1DM (new-onset), T1D (new-onset), Diabetes, Autoimmune, Alpha1-Proteinase Inhibitor, Alpha-1 Antitrypsin, AAT
Brief summary
Aralast NP (alpha-1 antitrypsin, AAT), an alpha-1 proteinase inhibitor (human), was the drug to be tested in this clinical trial. Aralast NP is an anti-inflammatory drug that affects the cells that are thought to be involved in the development of type 1 diabetes mellitus (T1DM, T1D). This study, known as RETAIN, was planned as a two-part trial to investigate the effect of Aralast NP on preserving beta cell function and to determine if the intervention would slow the progression of type 1 diabetes. Part I of this trial (NCT 01183468) was an open-label, safety and dose level study consisting of two groups. After completion of Part I, including a satisfactory safety review, enrollment in Part II was to begin. Part II was designed as a two-arm, double-blind, placebo-controlled clinical trial, and participants were to be randomly assigned to either the Aralast NP treatment or placebo group.
Detailed description
T1D is an autoimmune disease. This means that your immune system (the part of your body that helps fight infections) mistakenly attacks the cells that produce insulin (beta cells in the pancreas). As beta cells are destroyed by your immune cells, your ability to produce insulin is decreased. Insulin helps keep blood glucose levels normal. Individuals with T1D who have the ability to produce some of their own insulin (even though they still need to take insulin) may be able to achieve better glucose control than people who produce no insulin at all. Better glucose control has been shown to reduce the long-term complications of diabetes. Previous research has shown that giving medicines to affect the immune system soon after type 1 diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. In mouse models of disease, alpha-1 proteinase inhibitors have been shown to reverse new-onset diabetes and induce a state of self-tolerance. The RETAIN clinical trial was intended to investigate the effect of Aralast NP on preserving beta cell function and slowing the progression of T1D.
Interventions
DRUGAralast NP
Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
DRUGPlacebo
Participants will receive IV infusions of placebo once a week for 12 weeks.
Sponsors
Immune Tolerance Network (ITN)
Juvenile Diabetes Research Foundation
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
8 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with type 1 diabetes (T1D) within the past 100 days * Positive for at least one diabetes-related autoantibody (anti-GAD; anti-insulin, if obtained within 10 days of the onset of insulin therapy; IA-2 antibody and/or ICA, or ZnT8) * Peak stimulated C-peptide level greater than (\>) 0.2 pmol/mL following a mixed meal tolerance test (MMTT)
Exclusion criteria
* Severe active disease (hepatitis, cardiac or pulmonary disease, hypertension, immunodeficiency) * History of any bleeding or clotting factor deficiencies, or stroke * History of vascular disease or significant vascular abnormalities * Positive serology exposure to hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or toxoplasmosis * Clinically active infection with Epstein-Barr virus (EBV), cytomegalovirus (CMV), or tuberculosis (TB) * Prior or current use of oral, inhaled or intranasal glucocorticoids, or any medication known to cause a significant, ongoing change in the course of T1D or immunologic status * Prior treatment with alpha1-antitrypsin (AAT) or hypersensitivity to AAT or human plasma-derived products * Current or prior (within the last 30 days) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin * Current use of any medication known to influence glucose tolerance (e.g., beta-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine anti-malarial drugs, lithium, niacin) * Females who are pregnant or lactating, or are unwilling to defer pregnancy during study participation * Immunoglobulin A (IgA) deficiency * Uncontrolled hypertension * Current life-threatening malignancy * Any condition that in the investigator's opinion may compromise study participation or may confound the interpretation of the study results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mixed-Meal Tolerance Test (MMTT)-Stimulated 2-hour C-peptide Area Under the Curve (AUC) | Week 52 |
Secondary
| Measure | Time frame |
|---|---|
| MMTT-Stimulated Peak and 4-hour C-peptide AUC | Weeks 52 and 104 |
| MMTT-Stimulated 2-hour C-Peptide AUC Assessed Over Time | Weeks 0, 14, 26, 52, and 104 |
| Insulin Use in Units Per Kilogram Body Weight Per Day | Weeks 52 and 104 |
| Hypoglycemic Events Occurring from Randomization to End of Trial | Throughout the Study |
| Glycosylated Hemoglobin (HbA1c) Levels | Weeks 52 and 104 |
| Emergence of Anti-Alpha 1-Antitrypsin (AAT) Antibodies | Throughout the Study |
| Frequency and Severity of All Adverse Events (AEs) | Throughout the study |
| Changes in D-dimer Levels Indicating Alteration in Coagulant/Anticoagulant Balance | Throughout the study |
| Pharmacokinetic Parameters of Aralast NP | Throughout the study |
Countries
United States
Outcome results
None listed